文献速递中毒与环境急症消化、代谢与肾脏急症

丁丙诺啡与纳曲酮在阿片类物质使用障碍合并多种物质使用中的比较有效性

Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use.
PubMed 文献 · JAMA Netw Open · 2022-05-02
一句话结论合并多种物质使用障碍者启动丁丙诺啡的几率更低,但丁丙诺啡治疗日与药物相关中毒入院减少相关,口服纳曲酮未见保护关联。

该观察性比较有效性研究利用2011至2016年美国IBM MarketScan保险理赔数据,纳入12至64岁、主要诊断为阿片类物质使用障碍(OUD)的求治者179280例,评估合并其他物质使用障碍(SUD)者启动丁丙诺啡或纳曲酮的分布,以及药物相关中毒入院的比较有效性。合并SUD与启动丁丙诺啡的几率降低相关(RR 0.55),与启动纳曲酮的几率升高相关(缓释剂型RR 1.12;口服RR 1.95)。在12485例启动OUD药物并至少发生1次药物相关中毒者中,丁丙诺啡治疗日相比无药物日与中毒减少相关(合并SUD者OR 0.56;无合并SUD者OR 0.57),缓释纳曲酮观察到可比关联,口服纳曲酮未见保护关联。

要点

  • 合并SUD者启动丁丙诺啡的几率低于无合并SUD者(RR 0.55,95%CI 0.54-0.56)。
  • 合并SUD者启动缓释纳曲酮(RR 1.12,95%CI 1.05-1.20)和口服纳曲酮(RR 1.95,95%CI 1.86-2.03)的几率升高。
  • 合并SUD者丁丙诺啡治疗日相比无药物日与药物相关中毒减少相关(OR 0.56,95%CI 0.48-0.65)。
  • 无合并SUD者丁丙诺啡治疗日同样与中毒减少相关(OR 0.57,95%CI 0.53-0.63),缓释纳曲酮关联可比。
  • 口服纳曲酮未观察到对药物相关中毒的保护关联。

适用人群与场景

  • 12至64岁、主要诊断为OUD的求治者,数据来自2011至2016年美国IBM MarketScan保险理赔数据库。
  • 合并SUD定义为OUD治疗启动时或启动前6个月内诊断的SUD。
  • 排除美沙酮接受者。

诊断标准与关键阈值

  • 合并SUD定义为SUD诊断与OUD治疗启动同时或在其前6个月内。
  • 治疗分类为未用OUD药物的心理社会治疗,或启动丁丙诺啡或纳曲酮(包括缓释或口服)。

研究设计与关键结果

  • 观察性比较有效性研究,纳入179280例OUD个体(平均[SD]年龄33.2[11.0]岁;90196[50.5%]男性),102930例(57.4%)接受未用OUD药物的心理社会治疗。
  • 47488例合并SUD者中33449例(70.4%)未接受OUD药物,131792例无合并SUD者中69481例(52.7%)未接受OUD药物。
  • 合并SUD与启动丁丙诺啡的几率降低相关(RR 0.55,95%CI 0.54-0.56),与启动缓释纳曲酮(RR 1.12,95%CI 1.05-1.20)和口服纳曲酮(RR 1.95,95%CI 1.86-2.03)的几率升高相关。
  • 在12485例启动OUD药物且保险入组期间至少发生1次药物相关中毒者中,合并SUD者丁丙诺啡治疗日相比无药物日与中毒减少相关(OR 0.56,95%CI 0.48-0.65),无合并SUD者OR 0.57(95%CI 0.53-0.63)。
  • 缓释纳曲酮观察到可比关联,口服纳曲酮未观察到保护关联。

证据类型、等级与局限

  • 证据类型:观察性比较有效性研究,使用保险理赔数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,合并多种物质使用的OUD个体比无多种物质使用者更不可能启动丁丙诺啡和纳曲酮。
  • 作者认为,在启动OUD药物的个体中,合并多种物质使用与丁丙诺啡启动减少和纳曲酮启动增加相关,尽管丁丙诺啡对药物相关中毒具有保护关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Despite prevalent polysubstance use, treatment patterns and outcomes for individuals with opioid use disorder (OUD) and cooccurring substance use disorders (SUD) are understudied.

OBJECTIVE: To evaluate the distribution of buprenorphine and naltrexone initiation among individuals with OUD with vs without cooccurring SUD and to assess the comparative effectiveness associated with buprenorphine and naltrexone against drug-related poisonings.

DESIGN, SETTING, AND PARTICIPANTS: This observational comparative effectiveness study used insurance claims from 2011 to 2016 from the US IBM MarketScan databases to study initiation of medications for OUD (MOUD) among treatment-seeking individuals aged 12 to 64 years with a primary diagnosis of OUD. Cooccurring SUD was defined as SUD diagnosed concurrent with or in the 6 months prior to OUD treatment initiation. Treatment was codified as psychosocial treatment without MOUD or initiation or buprenorphine or naltrexone (including extended-release or oral). Methadone recipients were excluded from analysis. Data were analyzed from February 3, 2021, through February 26, 2022.

MAIN OUTCOMES AND MEASURES: Associations between cooccurring SUD diagnoses with treatment type were assessed with multivariable regression. The association of drug-related poisoning admissions with days covered with buprenorphine or naltrexone prescriptions vs days without prescriptions was assessed among MOUD initiators. Odds ratios from within-person fixed effects models were estimated as a function of MOUD and stratified by cooccurring SUDs.

RESULTS: Among 179 280 individuals with OUD (mean [SD] age, 33.2 [11.0] years; 90 196 [50.5%] men), 102 930 (57.4%) received psychosocial treatment without MOUD. Across 47 488 individuals with cooccurring SUDs, 33 449 (70.4%) did not receive MOUD, whereas across 131 792 individuals without cooccurring SUDs, 69 481 (52.7%) did not receive MOUD. Cooccurring SUD was associated with decreased odds of initiating buprenorphine (risk ratio [RR], 0.55 [95% CI, 0.54-0.56]) but increased odds of initiating naltrexone (extended release: RR, 1.12 [95% CI, 1.05-1.20]; oral: RR, 1.95 [95% CI, 1.86-2.03]). Among 12 485 individuals initiating MOUD who experienced at least 1 drug-related poisoning during insurance enrollment, buprenorphine treatment days were associated with decreased poisonings compared with days without MOUD for individuals with cooccurring SUD (odds ratio [OR], 0.56 [95% CI, 0.48-0.65]) and individuals without cooccurring SUD (OR, 0.57 [95% CI, 0.53-0.63]), with comparable associations observed for extended-release naltrexone. No protective association was observed for oral naltrexone.

CONCLUSIONS AND RELEVANCE: These findings suggest that individuals with OUD and polysubstance use were less likely to initiate buprenorphine and naltrexone than individuals without polysubstance use. Among individuals initiating MOUD, polysubstance use was associated with decreased buprenorphine and increased naltrexone initiation, despite buprenorphine's protective associations against drug-related poisoning.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Xu KY, Mintz CM, Presnall N, et al. Comparative Effectiveness Associated With Buprenorphine and Naltrexone in Opioid Use Disorder and Cooccurring Polysubstance Use. JAMA Netw Open. 2022. PMID: 35536575. doi:10.1001/jamanetworkopen.2022.11363

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。